Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Pieter L. Meenhorst"'
Autor:
Wim Quint, Eefje Jong, Remco Bakker, Jan Mulder, Pieter L. Meenhorst, Leen-Jan van Doorn, Bernhard Kleter, Paul H.M. Smits
Publikováno v:
Journal of Clinical Microbiology. 43:5936-5939
Infection with human immunodeficiency virus (HIV) and the resulting immunosuppression are associated with an increased risk for human papillomavirus (HPV) persistence and related malignancies. In the present study we investigated the prevalence of HP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37d822928246367eb8b702d51b2113f2
https://doi.org/10.1128/jcm.43.12.5936-5939.2005
https://doi.org/10.1128/jcm.43.12.5936-5939.2005
Autor:
J. W. Mulder, A. D. R. Huitema, Bregt S. Kappelhoff, E.C.M. van Gorp, Albert T. A. Mairuhu, Jos H. Beijnen, Pieter L. Meenhorst, Kristel M. L. Crommentuyn
Publikováno v:
British Journal of Clinical Pharmacology. 60:378-389
Aims To develop a population pharmacokinetic model for lopinavir in combination with ritonavir, in which the interaction between both drugs was characterized, and in which relationships between patient characteristics and pharmacokinetics were identi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5beb306d985b7b2c15e0bc9a3dd1c20d
https://doi.org/10.1111/j.1365-2125.2005.02455.x
https://doi.org/10.1111/j.1365-2125.2005.02455.x
Autor:
Jan W. Mulder, Pieter L. Meenhorst, Eric C. M. van Gorp, Alwin D. R. Huitema, Bregt S. Kappelhoff, Jan M. Prins, Jos H. Beijnen, Sanjay U. C. Sankatsing
Publikováno v:
British journal of clinical pharmacology, 60(3), 276-286. Wiley-Blackwell
Aims The aim of the study was to characterize the population pharmacokinetics of indinavir, define the relationship between the pharmacokinetics of indinavir and ritonavir, and to identify the factors influencing the pharmacokinetics of indinavir alo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d594c6256e2713ade086dca87f1bac96
https://doi.org/10.1111/j.1365-2125.2005.02436.x
https://doi.org/10.1111/j.1365-2125.2005.02436.x
Publikováno v:
Cancer Chemotherapy and Pharmacology. 55:488-496
Systemic chemotherapy is the treatment of choice for AIDS-related advanced Kaposi sarcoma. One principal schedule combines adriamycin (doxorubicin), bleomycin, and vincristine (ABV). We analysed the plasma concentrations of low-dose doxorubicin (Dx)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f520ec475ae63c487c0090c59baf948c
https://doi.org/10.1007/s00280-004-0900-4
https://doi.org/10.1007/s00280-004-0900-4
Autor:
Jan M. Prins, Alwin D. R. Huitema, Zeynep Yalvaç, Pieter L. Meenhorst, Jan W. Mulder, Bregt S. Kappelhoff, Jos H. Beijnen
Publikováno v:
Clinical pharmacokinetics. 44(8):849-861
Objective: The aim of this study was to characterise the population pharmacokinetics of efavirenz in a representative patient population and to identify patient characteristics influencing the pharmacokinetics of efavirenz, with the ultimate goal of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4b3d542306290eef4ab9d68207bc608
https://doi.org/10.2165/00003088-200544080-00006
https://doi.org/10.2165/00003088-200544080-00006
Autor:
Alwin D. R. Huitema, Albert T. A. Mairuhu, Eric C. M. van Gorp, Kristel M. L. Crommentuyn, Pieter L. Meenhorst, Jan Mulder, Jos H. Beijnen
Publikováno v:
Antiviral Therapy. 9:779-785
Therapeutic drug monitoring of protease inhibitors (PIs) is usually performed on plasma samples although their antiretroviral effect takes place inside cells. Little is known, however, about the intracellular accumulation and related plasma pharmacok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4523bc6c37cc4868912f66d92683d44c
https://doi.org/10.1177/135965350400900520
https://doi.org/10.1177/135965350400900520
Autor:
Jan W. Mulder, Albert T. A. Mairuhu, Eric C. M. van Gorp, Pieter L. Meenhorst, Jos H. Beijnen, Alwin D. R. Huitema, Monique M R de Maat
Publikováno v:
Therapeutic Drug Monitoring, 25, 3, pp. 367-73
Therapeutic Drug Monitoring, 25, 367-73
Therapeutic Drug Monitoring, 25, 367-73
Item does not contain fulltext The objective of this study was to evaluate plasma concentrations of nonnucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) within several dosing schemes in a cohort of HIV-infected patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fabe519a5f8cd42603402add4e912df
https://doi.org/10.1097/00007691-200306000-00018
https://doi.org/10.1097/00007691-200306000-00018
Autor:
Alwin D. R. Huitema, Jos H. Beijnen, Albert T. A. Mairuhu, Eric C. M. van Gorp, Jan W. Mulder, Monique M R de Maat, Pieter L. Meenhorst
Publikováno v:
Clinical Drug Investigation. 23:629-637
To evaluate the possible pharmacokinetic interactions between nevirapine and fluvoxamine or fluoxetine in patients with HIV-1 infection.Patients who were using fluvoxamine or fluoxetine concomitantly were chosen from an unselected cohort (n = 173) of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4155ffa1b4f03b3e7303bae4539a23b2
https://doi.org/10.2165/00044011-200323100-00002
https://doi.org/10.2165/00044011-200323100-00002
Autor:
Jos H. Beijnen, Alwin D. R. Huitema, Eric C. M. van Gorp, Jan Mulder, Pieter L. Meenhorst, Monique M R de Maat
Publikováno v:
British Journal of Clinical Pharmacology. 54:378-385
Aims To study the population pharmacokinetics of nevirapine and to identify relationships between patient characteristics and pharmacokinetics in an unselected population of patients attending our outpatient clinic. Methods Ambulatory HIV-1-infected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c64d8d61857e796e6f42a9709588fbed
https://doi.org/10.1046/j.1365-2125.2002.01657.x
https://doi.org/10.1046/j.1365-2125.2002.01657.x
Publikováno v:
Pharmacological Research. 46:195-201
The clinical pharmacology of itraconazole is presented in relation to its use in the treatment of fluconazole-resistant oropharyngeal candidosis. The oral solution is a new formulation of itraconazole in which itraconazole is solubilised with the use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e7a6a3710d1571908df89be0c1ce072
https://doi.org/10.1016/s1043-6618(02)00088-9
https://doi.org/10.1016/s1043-6618(02)00088-9